The 20th Asian Society of Gynecologic Oncology Congress (ASGO 2025) Held Grandly in Japan
The 20th Asian Society of Gynecologic Oncology Congress (ASGO 2025) was grandly held in Japan. As one of the highest-level academic events in the field of gynecologic oncology in the Asia-Pacific region, this congress brought together top global experts and scholars to discuss the latest advancements and future directions in the diagnosis and treatment of gynecologic cancers. An academic delegation from our hospital, consisting of Chief Physician Wang Yinfeng, Attending Physician Cao Zhu, and Attending Physician Yang Shizhou, was invited to attend. They each delivered oral presentations, showcasing cutting-edge research findings that sparked enthusiastic responses and high recognition from attending experts. This fully demonstrated the robust strength and international influence of our hospital in both basic and clinical research in gynecologic oncology.
During the conference, the three physicians delivered excellent presentations on their respective areas of expertise, covering frontier topics such as tumors related to disorders of sex development, and the molecular mechanisms of cervical and endometrial cancers.
Chief Physician WANG Yinfeng presented a study titled "Gonadal Carcinogenesis in Phenotypically Female Patients With 46XY Karyotype." This research focused on a clinically rare but high-risk patient population, systematically elaborating on the clinical characteristics, molecular basis, and management strategies of gonadal carcinogenesis in these individuals. Following the presentation, participating experts engaged in in-depth discussions with Dr. WANG regarding the early diagnosis, timing of prophylactic surgery, and personalized treatment plans for this disease, expressing full recognition for the valuable evidence-based guidance this study provides for clinical practice.
Attending Physician CAO Zhu presented a report titled "CSN5 overexpression promotes the integral progression of cervical cancer by enhancing ENO3-mediated glycolysis while inhibiting cell motility." This study innovatively revealed the dual mechanism of the oncoprotein CSN5 in cervical cancer progression: on one hand, it promotes tumor cell proliferation by enhancing ENO3-mediated glycolysis, while on the other hand, it surprisingly inhibits cell motility. The proposal of this "bidirectional regulation" model offers a new perspective for understanding the complex biological behavior of cervical cancer. The novel mechanism it reveals—"proliferation taking precedence over metastasis"—may provide new avenues for future targeted therapies for cervical cancer, garnering keen interest and positive feedback from scholars present.
Attending Physician YANG Shizhou shared his team's breakthrough findings in endometrial cancer research, presenting a report titled "NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis mediated Ca influx." This study is the first to elucidate the detailed mechanism by which the ion transport protein NHE7, via a novel signaling pathway—the cAMP/CREB/GRIN2B axis—regulates intracellular calcium concentration, thereby helping tumor cells "escape" senescence and achieve malignant progression. The research findings, noted for their significant innovativeness, provide a new theoretical foundation for the pathogenesis of endometrial cancer and suggest NHE7 as a potential therapeutic target, earning widespread acclaim from international peers.
The imultaneous presence of our hospital's three experts on the prestigious international academic stage of ASGO, delivering presentations, represents another concentrated affirmation of our hospital's scientific research and clinical standards by the international gynecologic oncology community. Through in-depth exchanges with world-renowned experts, we have not only showcased our hospital's academic excellence but also broadened our research horizons. This will undoubtedly further promote the comprehensive development and innovation of our hospital's gynecologic oncology discipline, ultimately benefiting a vast number of patients.
